131.86
price up icon0.02%   0.02
pre-market  Pre-mercato:  132.72   0.86   +0.65%
loading
Precedente Chiudi:
$131.84
Aprire:
$132.45
Volume 24 ore:
1.47M
Relative Volume:
0.87
Capitalizzazione di mercato:
$19.32B
Reddito:
$9.82B
Utile/perdita netta:
$1.48B
Rapporto P/E:
13.02
EPS:
10.13
Flusso di cassa netto:
$2.30B
1 W Prestazione:
+3.40%
1M Prestazione:
+6.74%
6M Prestazione:
-18.06%
1 anno Prestazione:
-43.68%
Intervallo 1D:
Value
$131.67
$133.66
Intervallo di 1 settimana:
Value
$127.53
$134.74
Portata 52W:
Value
$110.03
$238.00

Biogen Inc Stock (BIIB) Company Profile

Name
Nome
Biogen Inc
Name
Telefono
(781) 464-2000
Name
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Name
Dipendente
7,605
Name
Cinguettio
@biogen
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
BIIB's Discussions on Twitter

Confronta BIIB con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
BIIB
Biogen Inc
131.86 18.69B 9.82B 1.48B 2.30B 10.13
Drug Manufacturers - General icon
LLY
Lilly Eli Co
765.84 645.82B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
153.22 366.76B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
187.34 323.41B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
116.94 220.95B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
72.04 304.82B 43.59B 15.04B 10.74B 3.3766

Biogen Inc Stock (BIIB) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-28 Downgrade HSBC Securities Buy → Hold
2025-04-04 Downgrade Argus Buy → Hold
2025-02-11 Iniziato Bernstein Mkt Perform
2025-01-02 Downgrade Piper Sandler Overweight → Neutral
2024-12-20 Downgrade BMO Capital Markets Outperform → Market Perform
2024-12-16 Downgrade Stifel Buy → Hold
2024-12-10 Ripresa BofA Securities Neutral
2024-12-09 Downgrade Jefferies Buy → Hold
2024-11-18 Downgrade Needham Buy → Hold
2024-11-15 Iniziato Wolfe Research Peer Perform
2024-11-14 Iniziato Citigroup Neutral
2024-10-31 Downgrade Morgan Stanley Overweight → Equal-Weight
2024-10-10 Ripresa Raymond James Mkt Perform
2024-02-14 Reiterato Needham Buy
2024-02-14 Downgrade Wells Fargo Overweight → Equal Weight
2024-01-24 Downgrade UBS Buy → Neutral
2023-12-20 Ripresa Cantor Fitzgerald Overweight
2023-12-07 Aggiornamento Raymond James Mkt Perform → Outperform
2023-09-06 Iniziato HSBC Securities Buy
2023-07-27 Iniziato Scotiabank Sector Outperform
2023-07-24 Reiterato UBS Buy
2023-05-01 Aggiornamento Guggenheim Neutral → Buy
2023-04-17 Aggiornamento Piper Sandler Neutral → Overweight
2022-10-26 Aggiornamento Goldman Neutral → Buy
2022-10-13 Aggiornamento Stifel Hold → Buy
2022-10-07 Aggiornamento Argus Hold → Buy
2022-09-28 Aggiornamento BMO Capital Markets Market Perform → Outperform
2022-09-28 Aggiornamento Mizuho Neutral → Buy
2022-09-28 Aggiornamento Robert W. Baird Neutral → Outperform
2022-04-18 Aggiornamento Wells Fargo Equal Weight → Overweight
2022-03-08 Downgrade Stifel Buy → Hold
2022-03-03 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2022-02-04 Downgrade BMO Capital Markets Outperform → Market Perform
2022-02-04 Reiterato Barclays Equal Weight
2022-02-04 Reiterato BofA Securities Neutral
2022-02-04 Reiterato Cowen Outperform
2022-02-04 Reiterato Morgan Stanley Overweight
2022-02-04 Reiterato Needham Buy
2022-02-04 Reiterato Oppenheimer Outperform
2022-02-04 Reiterato RBC Capital Mkts Sector Perform
2022-02-04 Reiterato Robert W. Baird Neutral
2022-02-04 Reiterato Wedbush Neutral
2022-02-04 Reiterato Wells Fargo Equal Weight
2022-02-04 Reiterato Wolfe Research Peer Perform
2022-01-13 Downgrade Guggenheim Buy → Neutral
2022-01-12 Downgrade Piper Sandler Overweight → Neutral
2021-12-10 Ripresa Raymond James Mkt Perform
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-12-06 Iniziato Goldman Neutral
2021-11-19 Iniziato BMO Capital Markets Outperform
2021-09-23 Iniziato Needham Buy
2021-06-18 Aggiornamento Piper Sandler Neutral → Overweight
2021-06-14 Reiterato Truist Buy
2021-06-11 Aggiornamento Bernstein Mkt Perform → Outperform
2021-06-10 Aggiornamento UBS Neutral → Buy
2021-06-08 Aggiornamento Atlantic Equities Underweight → Neutral
2021-06-08 Reiterato Barclays Equal Weight
2021-06-08 Aggiornamento Citigroup Sell → Neutral
2021-06-08 Reiterato H.C. Wainwright Buy
2021-06-08 Reiterato Jefferies Buy
2021-06-08 Reiterato Morgan Stanley Overweight
2021-06-08 Reiterato RBC Capital Mkts Sector Perform
2021-06-08 Aggiornamento Robert W. Baird Underperform → Neutral
2021-06-08 Reiterato Stifel Buy
2021-06-08 Aggiornamento William Blair Mkt Perform → Outperform
2021-06-07 Aggiornamento BofA Securities Underperform → Neutral
2021-06-07 Aggiornamento Cowen Market Perform → Outperform
2021-06-07 Aggiornamento Raymond James Underperform → Mkt Perform
2021-02-05 Downgrade DZ Bank Buy → Hold
2021-01-29 Aggiornamento Stifel Hold → Buy
2020-11-10 Aggiornamento DZ Bank Hold → Buy
2020-11-09 Downgrade Atlantic Equities Neutral → Underweight
2020-11-09 Downgrade BofA Securities Neutral → Underperform
2020-11-09 Downgrade Cowen Outperform → Market Perform
2020-11-09 Reiterato H.C. Wainwright Buy
2020-11-04 Aggiornamento BofA Securities Underperform → Neutral
2020-11-04 Aggiornamento Jefferies Hold → Buy
2020-11-04 Aggiornamento Wells Fargo Equal Weight → Overweight
2020-10-28 Iniziato UBS Neutral
2020-07-27 Aggiornamento Morgan Stanley Underweight → Overweight
2020-06-22 Downgrade Barclays Overweight → Equal Weight
2020-06-22 Reiterato RBC Capital Mkts Sector Perform
2020-06-09 Downgrade Bernstein Outperform → Mkt Perform
2020-04-23 Downgrade Citigroup Neutral → Sell
2020-04-23 Downgrade Raymond James Mkt Perform → Underperform
2020-03-31 Iniziato Wolfe Research Peer Perform
2020-02-27 Iniziato Barclays Overweight
2020-01-27 Aggiornamento Canaccord Genuity Hold → Buy
2019-12-13 Aggiornamento Credit Suisse Underperform → Neutral
2019-12-02 Downgrade Robert W. Baird Neutral → Underperform
Mostra tutto

Biogen Inc Borsa (BIIB) Ultime notizie

pulisher
07:00 AM

Biogen Disappointed by INESSS Recommendation on SKYCLARYS™ and its Impact on Quebec Patients with Friedreich Ataxia – Company AnnouncementFT.com - Financial Times

07:00 AM
pulisher
04:35 AM

Wealth Enhancement Advisory Services LLC Acquires 11,504 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

04:35 AM
pulisher
Jun 04, 2025

Subcutaneous Biologics Market in 2025-2032 Detailed Study - openPR.com

Jun 04, 2025
pulisher
Jun 04, 2025

4,772 Shares in Biogen Inc. (NASDAQ:BIIB) Purchased by First County Bank CT - MarketBeat

Jun 04, 2025
pulisher
Jun 04, 2025

Czech National Bank Acquires 2,025 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 04, 2025
pulisher
Jun 04, 2025

Rhumbline Advisers Increases Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 04, 2025
pulisher
Jun 04, 2025

Biogen Inc. (NASDAQ:BIIB) Shares Acquired by GAMMA Investing LLC - MarketBeat

Jun 04, 2025
pulisher
Jun 03, 2025

Biogen to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Biogen

Jun 03, 2025
pulisher
Jun 03, 2025

Relapsing Remitting Multiple Sclerosis Market Set to Witness - openPR.com

Jun 03, 2025
pulisher
Jun 03, 2025

Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Ex-Biogen Chief Medical Officer Strengthens Entrada's Duchenne Program as Phase 1 Data Shows Promise - Stock Titan

Jun 03, 2025
pulisher
Jun 03, 2025

Neuromuscular Disease Therapeutics Market Growth Driven - openPR.com

Jun 03, 2025
pulisher
Jun 03, 2025

152,867 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

What is William Blair's Estimate for Biogen Q2 Earnings? - MarketBeat

Jun 03, 2025
pulisher
Jun 02, 2025

Lansforsakringar Fondforvaltning AB publ Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 02, 2025
pulisher
Jun 02, 2025

City Therapeutics Partners with Biogen - Global Legal Chronicle

Jun 02, 2025
pulisher
Jun 02, 2025

Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch

Jun 02, 2025
pulisher
Jun 02, 2025

Biogen Inc. (NASDAQ:BIIB) Holdings Raised by Centre Asset Management LLC - MarketBeat

Jun 02, 2025
pulisher
Jun 01, 2025

California State Teachers Retirement System Buys 2,811 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 01, 2025
pulisher
Jun 01, 2025

Biogen Inc. (NASDAQ:BIIB) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat

Jun 01, 2025
pulisher
Jun 01, 2025

Toronto Dominion Bank Has $11.11 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 01, 2025
pulisher
Jun 01, 2025

Lighthouse Financial LLC Acquires Shares of 2,100 Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 01, 2025
pulisher
May 31, 2025

Farmers Trust Co. Acquires 2,012 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

May 31, 2025
pulisher
May 30, 2025

Auxier Asset Management Sells 2,136 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

May 30, 2025
pulisher
May 30, 2025

Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks - Yahoo Finance

May 30, 2025
pulisher
May 30, 2025

Biogen Inc. (NASDAQ:BIIB) Shares Bought by Mackenzie Financial Corp - MarketBeat

May 30, 2025
pulisher
May 29, 2025

GF Fund Management CO. LTD. Makes New $5.24 Million Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

May 29, 2025
pulisher
May 29, 2025

Progressive Supranuclear Palsy Treatment Market Set to Witness GrowthBiogen, AbbVie - openPR.com

May 29, 2025
pulisher
May 29, 2025

PKO Investment Management Joint Stock Co Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

May 29, 2025
pulisher
May 29, 2025

Biogen and City Therapeutics partner to develop RNAi therapies - MSN

May 29, 2025
pulisher
May 29, 2025

Biogen Inc. (NASDAQ:BIIB) Shares Sold by USS Investment Management Ltd - MarketBeat

May 29, 2025
pulisher
May 29, 2025

Siemens Fonds Invest GmbH Grows Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

May 29, 2025
pulisher
May 29, 2025

Public Employees Retirement System of Ohio Sells 2,866 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

May 29, 2025
pulisher
May 29, 2025

Voloridge Investment Management LLC Invests $23.20 Million in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

May 29, 2025
pulisher
May 28, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $234.55 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

May 28, 2025
pulisher
May 28, 2025

Tauopathies Treatment Market Detailed in New Research ReportBiogen, AbbVie - openPR.com

May 28, 2025
pulisher
May 28, 2025

Amyotrophic lateral Sclerosis Market 2025-2032: Top Trends & - openPR.com

May 28, 2025
pulisher
May 28, 2025

Recombinant Dna Technology Market Generated Opportunities, - openPR.com

May 28, 2025
pulisher
May 28, 2025

In Vitro Monoclonal Antibodies Market is expected to reach US$ - openPR.com

May 28, 2025
pulisher
May 28, 2025

Biogen and City Therapeutics to develop RNAi therapy - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Biogen and City Therapeutics partner to advance RNAi therapies - World Pharmaceutical Frontiers

May 28, 2025
pulisher
May 28, 2025

Biogen Inc. (NASDAQ:BIIB) Holdings Lifted by Quantinno Capital Management LP - MarketBeat

May 28, 2025
pulisher
May 28, 2025

Woodline Partners LP Boosts Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

May 28, 2025
pulisher
May 27, 2025

Biogen’s SWOT analysis: stock faces challenges amid neuroscience potential - Investing.com

May 27, 2025
pulisher
May 27, 2025

Biogen’s SWOT analysis: stock faces challenges amid neuroscience potential By Investing.com - Investing.com UK

May 27, 2025
pulisher
May 27, 2025

Biogen Inc. (BIIB) Taps RNAi Therapy in City Therapeutics Deal - Yahoo Finance

May 27, 2025
pulisher
May 27, 2025

Biogen (NasdaqGS:BIIB) Partners With City Therapeutics in US$1 Billion RNAi Therapy Deal - simplywall.st

May 27, 2025

Biogen Inc Azioni (BIIB) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general PFE
$23.39
price up icon 0.17%
$109.02
price down icon 0.28%
$287.01
price down icon 0.88%
drug_manufacturers_general GSK
$40.80
price up icon 0.84%
drug_manufacturers_general MRK
$78.27
price up icon 1.46%
drug_manufacturers_general NVO
$72.04
price up icon 1.59%
Capitalizzazione:     |  Volume (24 ore):